Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis

2019 ◽  
Author(s):  
Keyword(s):  
Balloon Catheter ◽  
Efficacy And Safety ◽  
Stent Restenosis ◽  
In Stent Restenosis

scholarly journals Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis

Circulation ◽  
2009 ◽  
Vol 119 (23) ◽  
pp. 2986-2994 ◽  
Author(s):  
Martin Unverdorben ◽  
Christian Vallbracht ◽  
Bodo Cremers ◽  
Hubertus Heuer ◽  
Christian Hengstenberg ◽  
...  
Keyword(s):  
Balloon Catheter ◽  
Stent Restenosis ◽  
In Stent Restenosis

Stenting with Acclino (flex) for symptomatic intracranial stenosis as secondary stroke prevention

2020 ◽  
Vol 12 (11) ◽  
pp. 1127-1131
Author(s):  
Lukas Meyer ◽  
Hannes Leischner ◽  
Goetz Thomalla ◽  
Lars Udo Krause ◽  
Stephan Lowens ◽  
...  
Keyword(s):  
Intracranial Hemorrhage ◽  
Stroke Prevention ◽  
Balloon Catheter ◽  
Intracranial Stenosis ◽  
Secondary Stroke Prevention ◽  
Stent Patency ◽  
Fatal Stroke ◽  
Stent Restenosis ◽  
In Stent Restenosis

Background and purposeStroke recurrence is high in patients with symptomatic intracranial stenosis despite best medical treatment. Based on evidence from past studies using previous stent generations, elective intracranial stenting (eICS) is considered in a minority of patients. This study aims to report on experience performing eICS with a novel device combination.MethodsWe retrospectively reviewed data from three high volume stroke centers and analyzed patients that were treated with eICS for symptomatic intracranial stenosis using the Acclino (flex) stent and the NeuroSpeed balloon catheter (Acandis GmbH, Pforzheim, Germany). Study endpoints were periprocedural rates of stroke regardless of territory or death at discharge and at the time of follow-up after eICS. Safety evaluation included asymptomatic and symptomatic intracranial hemorrhage, serious adverse events related to the intervention, and evaluation of stent patency at the time of follow-up.ResultsThe median age of patients that met the inclusion criteria (n=76) was 69 years. Target vessels were located in the anterior circulation in 55.3% (42/76) of patients. The periprocedural stroke rate was 6.5% (fatal stroke 2.6%; non-fatal stroke 3.9%) at discharge after eICS. Asymptomatic intracranial hemorrhage was observed in 5.2% (4/76) of patients. Follow-up DSA revealed in-stent restenosis of 25% (15/60), and percutaneous transluminal angioplasty was performed again in 11.6% (7/60) of patients.ConclusionStenting for symptomatic intracranial stenosis with the Acclino (flex)/NeuroSpeed balloon catheter seemed to be safe and reinforces eICS as an endovascular therapy option for secondary stroke prevention. Future studies are warranted to confirm these findings and investigate antithrombotic strategies and in-stent restenosis to minimize periprocedural complications and guarantee long term stent patency.

Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study

2015 ◽  
Vol 11 (8) ◽  
pp. 926-934 ◽  
Author(s):  
Martin Unverdorben ◽  
Christian Vallbracht ◽  
Bodo Cremers ◽  
Hubertus Heuer ◽  
Christian Hengstenberg ◽  
...  
Keyword(s):  
Balloon Catheter ◽  
Stent Restenosis ◽  
In Stent Restenosis

scholarly journals Response to Letter Regarding Article, “Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis”

Circulation ◽  
2010 ◽  
Vol 121 (6) ◽  
Author(s):  
Bruno Scheller ◽  
Bodo Cremers ◽  
Martin Unverdorben ◽  
Ralf Degenhardt ◽  
Christian Vallbracht ◽  
...  
Keyword(s):  
Balloon Catheter ◽  
Stent Restenosis ◽  
In Stent Restenosis

scholarly journals Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter

2012 ◽  
Vol 5 (3) ◽  
pp. 323-330 ◽  
Author(s):  
Bruno Scheller ◽  
Yvonne P. Clever ◽  
Bettina Kelsch ◽  
Christoph Hehrlein ◽  
Wolfgang Bocksch ◽  
...  
Keyword(s):  
Balloon Catheter ◽  
Stent Restenosis ◽  
Long Term Follow Up ◽  
In Stent Restenosis

scholarly journals An Engineered Gene Nanovehicle Developed for Smart Gene Therapy to Selectively Inhibit Smooth Muscle Cells: An In Vitro Study

2020 ◽  
Vol 21 (4) ◽  
pp. 1530
Author(s):  
Ling-Yi Cheng ◽  
Yu-Chi Wang ◽  
Ming-Hong Chen ◽  
Fu-I Tung ◽  
Kuan-Ming Chiu ◽  
...  
Keyword(s):  
Smooth Muscle ◽  
Ex Vivo ◽  
Vascular Endothelial Cell ◽  
Balloon Catheter ◽  
In Vitro Study ◽  
Vitro Study ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

In-stent restenosis is a serious concern for patients treated through the stenting procedure, although this can be solved using drug-eluting stents and/or drug-eluting balloon catheters. However, the chemical agents released from the drug-eluting layer for inhibiting smooth muscle cell (SMC) migration are inevitably associated with damage to vascular endothelial cell (ECs). The present in vitro study used a distinct strategy, in which a smart gene (phEGR1-PKCδ, an engineered plasmid consists of an SMC-specific promoter (human early growth response 1, hEGR1 promoter) ligated with a gene encoding apoptosis-inducing protein (protein kinase C-delta, PKCδ) was incorporated into a novel gene vehicle (Au cluster-incorporated polyethylenimine/carboxymethyl hexanoyl chitosan, PEI-Au/CHC) to form the PEI-Au/CHC/phEGR1-PKCδ complex, which was proposed for the selective inhibition of SMC proliferation. It was found that the cell viability of SMCs receiving the PEI-Au/CHC/phEGR1-PKCδ complex under simulated inflammation conditions was significantly lower than that of the ECs receiving the same treatment. In addition, the PEI-Au/CHC/phEGR1-PKCδ complex did not demonstrate an inhibitory effect on EC proliferation and migration under simulated inflammation conditions. Finally, the PEI-Au/CHC/phEGR1-PKCδ complexes coated onto a balloon catheter used in percutaneous transluminal coronary angioplasty (PTCA) could be transferred to both the ECs and the SMC layer of Sprague Dawley (SD) rat aortas ex vivo. These preliminary in vitro results suggest that the newly developed approach proposed in the present study might be a potential treatment for reducing the incidence rate of in-stent restenosis and late thrombosis in the future.

Sign in / Sign up

Export Citation Format

Share Document